SQLite Web: event_store.db

Update row 39551 in events

seq

Primary key. INTEGER

id

TEXT NOT NULL

kind

TEXT NOT NULL

ts

TEXT NOT NULL

actor

TEXT

subject_entity_ids

TEXT

payload

{"created_at":"2026-04-14T02:04:49.876253+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:2eed6dc6bf6e806d","evidence_event_ids":["evt_3009b9227fa7"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001193125-26-153378.txt","as_of":"2026-04-14T02:04:49.876253+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001193125-26-153378.txt","company":"Travere Therapeutics, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001193125-26-153378.txt","article_chars":2498,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_06f1e5383ec6d9fa","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001193125-26-153378.txt","content_type":"text/plain","enriched_at":"2026-04-14T02:19:30.005415+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001193125-26-153378.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001193125-26-153378.txt","source_event_id":"evt_3009b9227fa7","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"144","fp":"9beebf90c398200c","kind":"sec_filing","published_at":"20260413","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["2026-04-13","2026-04-10","2026-02-04","2026-02-03","2013-02-20","2008-06-25"],"entities":[{"asset_class":"equity","name":"Travere Therapeutics, Inc.","relevance":"high","symbol":"TVTX","type":"issuer"},{"asset_class":"person","name":"Christopher Cline","relevance":"high","symbol":"","type":"reporting_owner"},{"asset_class":"broker","name":"Morgan Stanley Smith Barney","relevance":"medium","symbol":"","type":"brokerage_firm"}],"event_type":"listing","information_gaps":["The provided text does not explicitly state the total number of shares to be sold across all entries; it shows multiple quantity/value lines but does not clearly label which are the current vs prior transactions beyond the dates shown.","The filing\u2019s exact \u201ctransaction type\u201d and whether it is a single sale or multiple sales is not fully disambiguated from the excerpted lines.","No explicit prior-known state is included in the prompt, so the \u201cwhat changed vs prior known state\u201d cannot be determined from the provided text alone."],"key_facts":["SEC filing: Form 144 (conformed submission type 144) filed as of 2026-04-13 (accession number 0001193125-26-153378).","Subject company: Travere Therapeutics, Inc. (CIK 0001438533; SEC file number 001-36257).","Reporting owner: Christopher Cline (CIK 0001943192).","The filing states the sale is mandated by the issuer\u2019s election under its equity incentive plans to fund tax withholding via a \u201csell to cover\u201d transaction with a brokerage firm designated by the issuer.","The filing includes a statement that the sale does not represent a discretionary trade by the reporting person.","The filing includes \u201cRestricted Stock Unit Vesting\u201d and references settlement/vesting dates including 04/10/2026 and 04/13/2026 in the provided text.","The filing includes a quantity value shown as 65 (shares) and a date shown as 04/13/2026; additional prior entries show 02/03/2026 and 02/04/2026 with other quantities/values (exact interpretation beyond provided text is not specified)."],"numeric_claims":[{"label":"Form 144 filed as of date","value":"2026-04-13"},{"label":"Shares shown (one entry)","value":"65"},{"label":"EIN (issuer)","value":"262383102"},{"label":"SEC file number","value":"001-36257"}],"primary_claim":"Form 144 for Travere Therapeutics, Inc. was filed as of 2026-04-13 by reporting person Christopher Cline for a sell-to-cover sale tied to vested RSU tax withholding.","relevance_score":0.55,"sentiment":"neutral","source_quality":"high","summary":"Travere Therapeutics, Inc. filed a Form 144 on 2026-04-13 related to a \u201csell to cover\u201d transaction for tax withholding upon settlement of vested restricted stock units by reporting person Christopher Cline.","topics":["SEC Form 144","sell to cover","restricted stock units","tax withholding","insider sale","Travere Therapeutics"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 144 \u00b7 Travere Therapeutics, Inc. \u00b7 Filed 20260413","ticker":"TVTX","tickers":["TVTX"],"title":"TVTX filed 144","url":"https://www.sec.gov/Archives/edgar/data/1438533/0001193125-26-153378.txt"}}

TEXT NOT NULL

source_ref

TEXT

confidence

REAL (default 0.0

dedupe_key

TEXT

episode_id

TEXT

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel